MBRX is trading 17.5% down at $2.94 today. - This decline occurs despite Moleculin Biotech announcing positive preliminary unblinded efficacy results from its Phase 2/3 MIRACLE trial for Annamycin in AML. - Investors are reacting to ongoing dilution worries, including recent warrant exercises that expanded the share count to 7,065,000 as of June 29, 2026. - Selling pressure is also attributed to profit-taking after a sharp rally in recent trading sessions.